STAT3 and ovarian carcinoma: Other reports have illustrated that RHPN2 activates the STAT3 pathway and expedites the progression of ovarian cancer, and the use of the STAT3 inhibitors signally eases the malignant cell behaviors induced by RHPN2 [52].